News Conference News TCT 2025 DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES Yael L. Maxwell November 04, 2025
News Conference News AHA 2024 OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain Todd Neale November 18, 2024
News Conference News TCT 2023 LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI L.A. McKeown October 25, 2023
News Conference News TCT 2022 RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion Todd Neale September 21, 2022
News Conference News TCT 2020 IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs L.A. McKeown October 18, 2020
News Conference News CRT 2020 Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation Michael O'Riordan February 26, 2020
News Conference News CRT 2020 Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR L.A. McKeown February 24, 2020
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Conference News ESC 2019 For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI Todd Neale September 03, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News ESC 2018 My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More Shelley Wood September 14, 2018
News Conference News ESC 2018 ESC 2018: Trimming DAPT, New NOAC Niches, Aspirin Scrutiny for Primary Prevention, and More Shelley Wood August 20, 2018